<DOC>
	<DOCNO>NCT01962571</DOCNO>
	<brief_summary>This clinical trial aim prevent visual dysfunction optic nerve degeneration associate autoimmune optic neuritis systemic i.v . administration 33.000 IU erythropoietin 3 day . The primary objective determine efficacy erythropoietin compare placebo give add-on methylprednisolone assess measurement retinal nerve fibre layer thickness low contrast visual acuity 6 month acute optic neuritis .</brief_summary>
	<brief_title>Treatment Optic Neuritis With Erythropoietin : Randomised , Double-blind , Placebo-controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients eligible inclusion trial must meet following criterion : 1 . Written inform consent obtain accord international guideline local law 2 . Male female patient age ≥ 18 ≤ 50 year 3 . Patients ON 4 . First symptoms ON ≤ 10 day prior first administration investigational product 5 . High contrast visual acuity ( HCVA ) ≤ 0.5 ( decimal system ) 6 . Adequate OCT measurement available Patients eligible trial must meet following criterion : 1 . Patient without legal capacity unable understand nature , significance consequence trial 2 . Simultaneous participation another interventional trial could interfere trial and/or participation clinical trial within last 3 month enrolment trial 3 . Refractive anomaly : Hyperopia &gt; 5 dpt , myopia &lt; 7 dpt , astigmatism &gt; 3 dpt 4 . Media opacity 5 . Severe papillitis 6 . Previous ON 7 . Any optic nerve retinal disease 8 . Preexisting MS neurological disease 9 . Congenital disease : thrombophilia phenylketonuria 10 . Acquired disease : autoimmune disease , cardiovascular disease , diabetes mellitus , uncontrolled hypertension ( blood pressure &gt; 140 / 90 mm Hg ( cf . chapter 7.7.5 ) ) , malignancy , epilepsy , know tuberculosis ongoing unknown activity , acute gastrointestinal ulceration within last 3 month prior randomisation , acute viral , bacterial fungal infection , know infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus , Hepatitis C Virus , history colitis ulcerosa , diverticulitis , acute enteroanastomosis , know osteoporosis , history thromboembolic event , elevate haemoglobin level ( &gt; 17 g/dl men &gt; 15 g/dl woman ) polycythaemia significant illness potentially interfere trial assessment trial treatment 11 . Performing semiprofessional professional sporting activity physical training 12 . Pretreatment corticosteroid last 30 day prior onset optic neuritis 13 . Pretreatment EPO 14 . Known persistent abuse medication , drug alcohol 15 . Active immunization within 2 week prior randomisation 16 . Significant surgery within 4 week prior randomisation 17 . Blood donation bloodletting within 4 week prior screen 18 . Pretreatment immunosuppressive immunomodulatory agent 19 . Persons relationship dependence/employment sponsor investigator This section concern female patient able child : 20 . Current planned pregnancy ; nursing period within 3 month investigational product administration 21 . Unwillingness use one follow safe combination method contraception within 3 month investigational product administration achieve PEARL index &lt; 1 : female condom , diaphragm coil , use combination spermicide ; hormonal intrauterine device hormonal contraception combination mechanical method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Optic neuritis</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Clinically isolated syndrome</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>